1a/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus.

ABSTRACT: The RNA-dependent RNA polymerase (NS5B) of hepatitis C virus (HCV) is an unusually attractive target for drug discovery since it contains five distinct drugable sites. The success of novel antiviral therapies will require nonnucleoside inhibitors to be active in at least patients infected with HCV of subtypes 1a and 1b. Therefore, the genotypic assessment of these agents against clinical isolates derived from genotype 1-infected patients is an important prerequisite for the selection of suitable candidates for clinical development. Here we report the 1a/1b subtype profiling of polymerase inhibitors that bind at each of the four known nonnucleoside binding sites. We show that inhibition of all of the clinical isolates tested is maintained, except for inhibitors that bind at the palm-1 bindi

SUBMITTER: Nyanguile O 

PROVIDER: S-EPMC2826027 | biostudies-literature | 2010 Mar

REPOSITORIES: biostudies-literature